Hemgenix (Etranacogene Dezaparvovec)

Hemgenix is indicated for adult patients with hemophilia B (factor IX deficiency) to provide sustained endogenous factor IX production.

• Long‑term reduction of bleeding episodes.
• Decreased need for regular factor IX replacement infusions.
• Potential improvement in joint health and quality of life.
• Use in patients who have developed inhibitors to conventional factor IX products.
• May be considered when standard prophylaxis is insufficient or not tolerated.

The safety profile of Hemgenix includes both common and serious adverse events observed in clinical studies.

Common

• Transient elevation of liver enzymes (ALT, AST).
• Mild flu‑like symptoms such as fever or fatigue.
• Injection‑site reactions including redness or discomfort.
• Nausea or mild gastrointestinal upset.

Serious

• Immune‑mediated hepatitis or severe liver injury.
• Thrombotic microangiopathy.
• Anaphylactic or severe allergic reactions.
• Development of neutralizing antibodies reducing efficacy.

Before initiating Hemgenix, clinicians should evaluate several precautionary factors to minimize risk.

• Baseline liver function tests and regular monitoring during treatment.
• Screening for pre‑existing antibodies to the AAV vector.
• Caution in patients with a history of hepatic disease or elevated transaminases.
• Avoid use in pregnant or breastfeeding individuals until safety data are available.
• Assess for concurrent use of immunosuppressive therapy.
• Consider age and overall health status, as therapy is approved for adults only.

Hemgenix may interact with other medications, requiring careful management of concomitant therapies.

Avoid

• Concurrent use of strong immunosuppressants that could diminish vector efficacy.
• Co‑administration with other gene‑therapy products targeting the liver.

Use with caution

• Anticoagulants or antiplatelet agents, due to potential changes in bleeding risk.
• Hepatotoxic drugs such as certain antibiotics or antifungals.
• Live vaccines, because of altered immune response.
• Other biologic agents that may affect immune modulation.